NTR vs. BMY

Last updated Apr 2, 2026

Compare and contrast key facts about Nutrien Ltd. (NTR) and Bristol-Myers Squibb Company (BMY).

Performance

NTR vs. BMY - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Nutrien Ltd. (NTR) and Bristol-Myers Squibb Company (BMY). The values are adjusted to include any dividend payments, if applicable.

NTR vs. BMY - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018
NTR Nutrien Ltd.	21.68%	43.33%	-16.97%	-20.19%	0.23%	60.78%	5.60%	5.57%	-11.36%
BMY Bristol-Myers Squibb Company	15.79%	0.11%	15.81%	-26.14%	18.98%	2.88%	0.41%	27.74%	-12.94%

Fundamentals

Market Cap NTR : $36.03B BMY : $125.99B
EPS NTR : $4.68 BMY : $3.46
PE Ratio NTR : 15.94 BMY : 17.84
PEG Ratio NTR : 0.24 BMY : 1.02
PS Ratio NTR : 1.35 BMY : 2.61
PB Ratio NTR : 1.43 BMY : 2.26
Total Revenue (TTM) NTR : $26.90B BMY : $48.19B
Gross Profit (TTM) NTR : $8.35B BMY : $30.43B
EBITDA (TTM) NTR : $5.98B BMY : $13.82B

Returns By Period

In the year-to-date period, NTR achieves a 21.68% return, which is significantly higher than BMY's 15.79% return.

NTR

• 1D: -1.19%
• 1M: -0.85%
• YTD: 21.68%
• 6M: 33.78%
• 1Y: 55.76%
• 3Y*: 4.29%
• 5Y*: 10.29%
• 10Y*: —

BMY

• 1D: 1.78%
• 1M: -0.98%
• YTD: 15.79%
• 6M: 33.50%
• 1Y: 8.90%
• 3Y*: 0.70%
• 5Y*: 3.49%
• 10Y*: 2.90%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

NTR vs. BMY — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

NTR

NTR Risk / Return Rank: 87
NTR Sharpe Ratio Rank: 88
NTR Sortino Ratio Rank: 85
NTR Omega Ratio Rank: 82
NTR Calmar Ratio Rank: 91
NTR Martin Ratio Rank: 89

BMY

BMY Risk / Return Rank: 47
BMY Sharpe Ratio Rank: 52
BMY Sortino Ratio Rank: 45
BMY Omega Ratio Rank: 44
BMY Calmar Ratio Rank: 47
BMY Martin Ratio Rank: 45

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

NTR vs. BMY - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Nutrien Ltd. (NTR) and Bristol-Myers Squibb Company (BMY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	NTR	BMY	Difference
Sharpe ratio Return per unit of total volatility	1.80	0.31	+1.49
Sortino ratio Return per unit of downside risk	2.46	0.64	+1.82
Omega ratio Gain probability vs. loss probability	1.31	1.08	+0.23
Calmar ratio Return relative to maximum drawdown	4.20	0.25	+3.95
Martin ratio Return relative to average drawdown	10.11	0.39	+9.71
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

NTR vs. BMY - Sharpe Ratio Comparison

The current NTR Sharpe Ratio is 1.80, which is higher than the BMY Sharpe Ratio of 0.31. The chart below compares the historical Sharpe Ratios of NTR and BMY, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	NTR	BMY	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	1.80	0.31	+1.49
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	0.30	0.15	+0.16
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	—	0.12	—
Sharpe Ratio (All Time) Calculated using the full available price history	0.23	0.35	-0.13

Correlation

The correlation between NTR and BMY is 0.19, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

NTR vs. BMY - Dividend Comparison

NTR's dividend yield for the trailing twelve months is around 2.93%, less than BMY's 4.03% yield.

	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
NTR Nutrien Ltd.	2.93%	3.53%	4.83%	3.76%	3.51%	2.45%	3.74%	3.67%	3.47%	0.00%	0.00%	0.00%
BMY Bristol-Myers Squibb Company	4.03%	4.60%	4.24%	4.44%	3.00%	2.36%	3.69%	2.55%	3.08%	2.55%	1.95%	2.17%

Drawdowns

NTR vs. BMY - Drawdown Comparison

The maximum NTR drawdown since its inception was -57.80%, smaller than the maximum BMY drawdown of -72.03%. Use the drawdown chart below to compare losses from any high point for NTR and BMY.

Drawdown Indicators

	NTR	BMY	Difference
Max Drawdown Largest peak-to-trough decline	-57.80%	-72.03%	+14.23%
Max Drawdown (1Y) Largest decline over 1 year	-13.20%	-25.79%	+12.59%
Max Drawdown (5Y) Largest decline over 5 years	-57.80%	-47.67%	-10.13%
Max Drawdown (10Y) Largest decline over 10 years	—	-47.67%	—
Current Drawdown Current decline from peak	-24.29%	-12.07%	-12.22%
Average Drawdown Average peak-to-trough decline	-26.15%	-22.40%	-3.75%
Ulcer Index Depth and duration of drawdowns from previous peaks	5.48%	16.06%	-10.58%

Volatility

NTR vs. BMY - Volatility Comparison

Nutrien Ltd. (NTR) has a higher volatility of 13.66% compared to Bristol-Myers Squibb Company (BMY) at 6.68%. This indicates that NTR's price experiences larger fluctuations and is considered to be riskier than BMY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	NTR	BMY	Difference
Volatility (1M) Calculated over the trailing 1-month period	13.66%	6.68%	+6.98%
Volatility (6M) Calculated over the trailing 6-month period	25.30%	19.39%	+5.91%
Volatility (1Y) Calculated over the trailing 1-year period	31.05%	28.61%	+2.44%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	33.98%	23.68%	+10.30%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	33.99%	25.08%	+8.91%

Financials

NTR vs. BMY - Profitability Comparison

The chart below illustrates the profitability comparison between Nutrien Ltd. and Bristol-Myers Squibb Company over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

NTR - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Nutrien Ltd. reported a gross profit of 1.92B and revenue of 5.42B. Therefore, the gross margin over that period was 35.4%.

BMY - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Bristol-Myers Squibb Company reported a gross profit of 6.24B and revenue of 12.50B. Therefore, the gross margin over that period was 49.9%.

NTR - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Nutrien Ltd. reported an operating income of 800.11M and revenue of 5.42B, resulting in an operating margin of 14.8%.

BMY - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Bristol-Myers Squibb Company reported an operating income of 1.47B and revenue of 12.50B, resulting in an operating margin of 11.8%.

NTR - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Nutrien Ltd. reported a net income of 579.78M and revenue of 5.42B, resulting in a net margin of 10.7%.

BMY - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Bristol-Myers Squibb Company reported a net income of 1.09B and revenue of 12.50B, resulting in a net margin of 8.7%.